BioSpace News Archive

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and, nasal care, disinfectant use and dermatological conditions today announced financial results for its first fiscal quarter ended June 30, 2021.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2022 ended June 30, 2021.

Carl Zeiss Industrial Metrology, LLC has partnered with Oak Ridge National Laboratory on a project chosen to receive funding through the U.S. Department of Energy’s Technology Commercialization Fund project solicitation.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.

Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today reported financial results for the quarter ended June 30, 2021, and provided a summary of recent corporate highlights.

StageZero Life Sciences, Ltd, a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, announced the signing of a share purchase agreement to acquire all of the shares of Clinics Operations Limited, a provider of specialist clinical services across Europe and North America, and wholly owned subsidiary of Health Clinics Limited.

CollPlant (Nasdaq: CLGN), today announced that Dr. Nadav Orr, Vice President of R&D, will present on August 19, 2021, an overview on the use of collagen Bionks for 3D Bioprinting, during the Biomaterials For 3D Printing webinar by 3DHEALS LLC.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of mRNA-3705, its investigational mRNA therapeutic for methylmalonic acidemia (MMA), administered via intravenous infusion in patients with isolated MMA due to MUT deficiency.

Modular Medical, Inc. today announced the expansion of its executive team with the appointment of Lynn O’Connor Vos as its new Chief Executive Officer.

Ascletis Pharma Inc. (HKEX:1672) today announces that its partner Sagimet Biosciences dosed the first patient in its FASCINATE-2 Phase IIb clinical trial for non-alcoholic steatohepatitis (NASH).